FDA Clearance Tracker · P140033-S089
The Tendril MRI lead
Last checked: Nov 20, 2026Latest source record: Jul 2, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Jul 2, 2024
Approved
Time to decision
67 days
Received Apr 26, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P140033-S089
- Device name
- The Tendril MRI lead
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Sylmar, CA
- Received
- Apr 26, 2024
- Decided
- Jul 2, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P140033
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
approval for a labeling update to include the findings of the SJM Brady MRI Post-Approval Study.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.